Approved for use through 10/31/2002. OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known
Application Number	Unassigned
Filing Date	July 11, 2003
First Named Inventor	Elisabeth DEFOSSA et al.
Group Art Unit	Unassigned (625
Examiner Name	Unassigned ZNDAVE /C/
Attorney Docket Number	38005-0178

RIARIE .	Under	the Paperwork Reduction A	ct of 1995, n	o persons an	e required to respor	nd to a collection of in	nformation	unless it contains a valid OMB control number	•
Substitut	e for form	1449A/PTO					Compl	lete if Known	,
					Application No	ımber	Unas	ssigned	98 <sub>-</sub>
INFO	RMA	TION DISCL	OSUF	RE	Filing Date		July	11, 2003	Co.
STA	TEME	NT BY APP	LICAN	IT	First Named I	nventor	Elisa	beth DEFOSSA et al. 0	. SIVA
• • • • • • • • • • • • • • • • • • • •					Group Art Uni	t	Unas	ssigned 1625	
	(use as	many sheets as nece	essary)		Examiner Nar	ne	Unas	Seigned ZNDAUK CLYO	3200
Sheet	1	of 4			Attorney Dock	et Number	3800	05-0178	RECEIVE.
	<del>-1</del>								54 1600
				U.S. PA	TENT DOCU	MENTS			ER 1600/2900
	0,1-	U.S. Patent Docum	ent		of Patentee or	Date of Publica			1000
Examiner Initials *	Cite No.1	Number Kind Cod			pplicant ed Document	Cited Docum		Passages or Relevant Figures Appear	·
Arond	A01	6,221,633	B1	Er	tl et al.	4/24/200	01		
**	A02	6,221,897	B1	Frie	ck et al.	4/24/200	01		
<b>J</b>	A03	6,245,744	B1	Frie	ck et al.	6/12/200	<b>D1</b>		
mod	A04	6,342,512	B1 `	Kirs	ch et al.	1/29/200	02		<b>1</b>
7 3									
	<del>  </del>								1
	1 1				4.				1
	· ·								

				FC	DREIGN	PATENT DOCUMENTS			
			For	eign Patent Docum			Date of	Pages, Columns, Lines, Where	
Exam Initia		Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T <sub>B</sub>
M	(C)	A05	EP	0 221 847	A2	Ciba-Geigy AG	5/13/1987		
4		A06	wo	97/26265	A1	Novo Nordisk A/S	7/24/1997		
	4	A07	wo	97/41097	A2	Dr. Reddy's Research Foundation	11/6/1997		
	•	A08	wo	98/08871	A1	Novo Nordisk A/S	3/5/1998		
		A09	wo	99/03861	A1	Novo Nordisk A/S	1/28/1999		
		A10	wo	99/15525	A1	Sanofi	4/1/1999		
	7	A11	wo	00/40569	A1	Alizyme Therapeutics Limited	7/13/2000		
V	٢,_	ع A12	wo	00/63208	A1	Novo Nordisk A/S	10/26/2000		
m	A	A13 •	wo	00/64888	A1	Aventis Pharmaceuticals	11/2/2000		

Examiner Signature	In NDavis	Date Considered	1/	12/2005

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.

e a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031\*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

			e: U.S. DEPARTMENT OF COMMERCE unless it contains a valid OMB control number	
		Comple	ete if Known	
Application Nu	ımber	Unas	signed	CA
Filing Date		July 1	11, 2003	
First Named I	nventor	Elisal	beth DEFOSS et a	1. 8
Group Art Uni	1	Unas	signed	620
Examiner Nan	ne	Unas	signed SN/7	2003
Attorney Dock	et Number	3800	5-0178	160
				1 1600/2900
TENT DOCU	MENTS			1300
of Patentee or	Date of Public Cited Docu		Pages, Columns, Lines, Where Relevant Passages or Relevant	

				U.S. PATENT DOCL	JMENTS	
		U.S. P	alent Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	No.	Number	Kind Code <sup>2</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
				••		
	1	1				

				FOREIG	N PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	For Office <sup>3</sup>		ment ind Code <sup>5</sup> if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>e</sub>
and	A14 <sub>B</sub>	wo	00/64876	A1	Aventis Pharmaceuticals	11/2/2000		
水	A15	wo	00/66585	A1	Neurogen Corp.	11/9/2000		
	A16 •	wo	00/71549	A1	Knoll Aktiengesellschaft	11/30/2000		
	A17	wo	00/78312	A1	Merck & Co., Inc.	12/28/2000		
	A18	wo	01/09111	A1	Eli Lilly & Co.	2/8/2001		
	A19	wo	01/83451	A1		11/8/2001		
	A20	wo	01/85695	A1	Bristol-Myers Squibb	11/15/2001		
1	A21 6	wo	·01/91752	A1	Merck & Co., Inc.	12/6/2001		
m	A22 «	DE.	10142734	A1	Aventis Pharma Deutschland GmbH	3/27/2003		

9			
Examiner Signature: When Word	Date Considered	1/12/200	) <i>5</i>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.

O The lease type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Cite

Examiner

Initiats

	Complete if Known	Pro
Application Number	Unassigned	TCA,
Filing Date	July 11, 2003	J. VED
First Named Inventor	Elisabeth DEFOSS et al	$\mathcal{I}_{15}$
Group Art Unit	Onassigned_ 1625 CH 0	2003
Examiner Name	Unassigned ZNDAVLY	/24 2
Attorney Docket Number	38005-0178	199 1600 C
		_ 000/2900
ENT DOCUMENTS		
		I

**U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Date of Publication of Pages, Columns, Lines, Where Relevant Applicant of Cited Document Cited Document Passages or Relevant Kind Code<sup>2</sup> Number Figures Appear MM-DD-YYYY (if known)

				FOREIG	N PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	For Office <sup>3</sup>	eign Patent Do	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
(Mary	A23	EP	0462884	B1	ADIR Et Compagnie	12/27/1991		
- U								
						··-		
			<del>                                     </del>					
		<del>                                     </del>		<del> </del>				
				<del></del>				
		}						
		1				1		1

Examiner Signature Zunn Davis Date Considered 1/12/2005						
	Signature	Linn	N. Cairs	1/12	2005	

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many s	heets as	necessary)
4	of	4

Complete if Known				
Application Number	10/616,959			
Filing Date	July 11, 2003			
First Named Inventor	Elisabeth DEFOSSA et al.			
Group Art Unit	Unassigned 1625			
Examiner Name	Unassigned ZNDAYIS			
Attorney Docket Number	38005-0178			

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
Mode	) A24	A. ASAKAWA et al., "Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice", Horm. Metab. Res., 2001, pp. 554-558, Vol. 33					
1	A25	P. DRUECKES et al., "Photometric Microtiter Assay of Inorganic Phosphate in the Presence of Acid-Labile Organic Phosphates", Analytical Biochemistry, 1995, p. 173-177, Vol. 230					
	A26	H.D. ENGERS et al., "Kinetic mechanism of phosphorylase a. I. Initial velocity studies", Department of Biochemistry, University of Alberta, Edmonston 7, Alberta, January 12, 1970, pp. 746-754					
	A27	DANIEL W. LEE et al., "Leptin agonists as a potential approach to the treatment of obesity", Drugs of the Future, 2001, pp. 873-881, Vol. 26, No. 9					
	A28	HIROSHI OKADA et al., "Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas", Chem. Pharm. Bull., 1994, pp. 57-61, Vol. 42, No. 1					
	A29	JAVIER SALVADOR et al., "Perspectives in the therapeutic use of leptin", Expert Opin. Pharmacother, 2001, 2001, pp. 1615-1622, Vol. 2, No. 10					
<b>\</b>	A30	PRAVENN TYLE, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, 1986, pp. 318-326, Vol. 3, No. 6					
mod	A31	H.J.F. ZUNFT et al., "Carob Pulp Preparation for Treatment of Hypercholesterolemia", Advances in Natural Therapy", September/October 2001, pp. 231-236, Vol. 18, No. 5					

Examiner		Date	1 /	1.12
Signature	•	Considered	' <i></i>	12/2003

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of lime you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

0 9 2003

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/616,959 NFORMATION DISCLOSURE Filing Date July 11, 2003 STATEMENT BY APPLICANT Elisabeth DEFOSSA et al. First Named inventor Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** <del>1614</del>-Sheet of 1 Attorney Docket Number 38005-0178

	U.S. PATENT DOCUMENTS							
Examiner Cite No.1		U.S. P	atent Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant		
	Number (if known)		Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
					,			
	ļ	-						
	ļ							
•			ĺ					

			FC	OREIGN I	PATENT DOCUMENTS			
		Foreign Patent Document				2	Pages, Columns,	
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Lines, Where Relevant Passages or Relevant Figures Appear	Т6
me	B01	WIPO	02/096864	A1	Aventis Pharma Deutschland GmbH	12/5/2002		
1	B02	WIPO	01/94300	A1	Aventis Pharma Deutschland GmbH	12/13/2001		
	B03	JP	01034953	A2	Aguro Kanesho KK	6/2/1989		
	B04	EP	0 166 729	A2	Duphar International Research B.V.	8/29/1984		
1	B05	EP	0 167 197	A1	Duphar International Research B.V.	8/1/1986		
mo	B06	EP	0 221 847	A2	CIBA-GEIGY AG	5/13/1987		
						·		

Examiner Signature	Line Webarrs	Date Considered	1/12	2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not im conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.